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Abstract: 
Background: Individuals who are treated with antipsychotic medications especially 
atypical group are facing several metabolic and biochemical changes that might put them 
at higher risk of developing several diseases. The aim of this study was to evaluate the 
fasting blood glucose level and lipid profile among those with common psychotic 
disorders under effect of atypical antipsychotic drugs compared with healthy population.  
Materials and Methods: A laboratory- based case control study was conducted and 
carried out in Khartoum State (AlTigani AlMahy Hospital for Psychotic and Mental 
Diseases) from May to November 2017. The samples were drawn from fifty patients of 
common psychotic disorders as case group and another fifty from healthy individuals as 
control group to estimate the level of fasting blood glucose and lipid profile using 
Mindary Biosystems PS200. 
Results: out of 50 cases, 52% were males and 48% females. It was found that there was a 
significant increase in mean of all tested parameters, fasting blood glucose (FBG) 
(109.19±26.27), Total Cholesterol (167.23±41.79), Triglyceride (161.80±59.29) and Low 
Density Lipoprotein (LDL) (66.42±16.72) but decrease in High Density Lipoprotein 
(HDL) (53.96±17.86), all with (p.value 0.00) compared to control. There was no 
correlation between parameters and age, but positive correlation was observed between 
LDL and duration (R-0.047).   
Conclusion: Individuals under atypical antipsychotic medications had higher levels of 
fasting blood glucose and lipid profile than normal individuals. 
Key words: A typical antipsychotic drugs, Lipid profile, Blood glucose level. 
Introduction: 
Psychosis is a mental disorder characterized by disordered thought processes blunted or 
inappropriate emotional responses bizarre behavior ranging from hypo activity to 
hyperactivity with agitation, aggressiveness, hostility, and combativeness; social in which 
a person pays less-than-normal attention to the environment and other people. Psychosis 
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can be chronic or acute.
(1)
 There are diseases which can present with psychosis, the most 
common of them  (Schizophrenia, Bipolar and major Depressive disorders). 
Schizophrenia is one of the most serious and frightening of all mental illnesses.
(2)
 Bipolar 
disorder is a major public health problem associated with significant morbidity and a high 
mortality risk.
(3)
 Depression is a seriously disabling public health problem of very high 
prevalence.
(4)
 Psychiatric patients treated by different types of antipsychotic drugs 
especially typical group which cause different changesin human body physiology and 
biochemistry such as; Olanzapine, Risperidone and Clozapine.
(5, 6) 
In several studies that  were done in patients who received typical antipsychotic drugs  
(clozapine , olanzapine , benztropine , risperidone )  for schizophrenia and bipolar 
disorder and others, they found that  hyperglycemia might  result from  changes in 
glucose  regulation leading to impaired glucose tolerance and insulin resistance,these may 
put them in a pre-diabetic status,diabetes mellitus type 2 (DM type2) or other metabolic 
syndromes. The risk of developing diabetes mellitus and other complications is deferring 
form using one drug to another. 
(7-11) 
Schizophrenia has high prevalence of diabetes 
mellitus 2 to 4 times more prevalent than in the general population. 
(12) 
The mechanism of insulin resistance thought from the ability of antipsychotic drugs to 
inhibit caracole induced insulin secretion by the pancreatic β-cell was, at a relatively high 
concentration, due to lower receptor affinity, similar to the muscarinic receptor antagonist 
atropine. The effect of drugs in glucose and insulin level is shown according to dose and 
time,highest effect is seen in high dose and longtime of using treatment. 
(13) 
Several studies investigated the relationship between psychiatric patients who were 
treated with anti-psychiatric medications specially a typical one and lipid profile; results 
found  increase in total cholesterol (TC), triglycerides (TG), low density lipoprotein 
cholesterol (LDL), very low density lipoprotein cholesterol (VLDL) and decrease in high 
density lipoprotein cholesterol (HDL), but had greater effect on triglyceride 
concentration).
(14,15)
 
Other studies showed that patients with an established psychotic illness with expected 
consequences had a higher rate for developing cardiovascular disease, coronary heart 
disease, infection, inflammation and accidental death.
 (10, 16) 
 
Materials and Methods: 
This is a Laboratory- based case control study which was conducted from May to 
November 2017 in AlTigani AlMahy Hospital Khartoum - Sudan. It included Sudanese 
hospitalized psychiatric patients who received a typical antipsychotic medications for 
diagnosed common psychotic disorders (Bipolar, schizophrenia and major Depressive 
disorder). One hundred subjects were recruited for this study fifty represented case group 
and fifty as control group. This study was conducted to analyze the parameters of lipid 
profile, fasting blood glucose and studied the correlation between these variables. 
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Ethical considerations: 
The study was approved by the department of clinical chemistry-faculty of medical 
laboratory Sciences-Sudan International University. Also a verbal consent was obtained 
from patients directly or indirectly from their relatives. 
Sampling collection and processing: 
Following aseptic techniques, 3ml of venous blood was collected from the group of the 
study and control group (fasting sample). Then centrifuged and stored in refrigerator -20 
until tested for estimation of (glucose and lipid profile) which was done by fully 
automated chemistry analyzer Mindary BS 200. 
 
Statistical analysis: 
Data were analyzed using SPSS version 21. Expressed as Mean, Standard deviation and 
percentage. Independent T test was used to compare between the mean of study 
parameters (glucose, total cholesterol, triglyceride, HDL, LDL) in case and control and 
Pearson correlation was done to study the correlation between analyzed parameters and 
study variables (duration and age). P value ≤ 0.05 considered as significance.  
 
Results: 
The descriptive statistics of the study showed that the case group included 52% males and 
48% females (figure 1), and the results showed that the mean concentration of fasting 
blood glucose level was significantly increased in psychiatric patients (109.19±26.27) 
compared to control group (72.22±19.73) with P.value 0.00 (figure 2). The mean 
concentration of total cholesterol was significantly increased in psychiatric patients 
(167.23±41.79) compared to control group(113.88±18.23) with P.value 0.00 (figure 3). 
The mean concentration of triglyceride was significantly increased in psychiatric patients 
(161.80±59.29) compared to control group (100.93±23.79) with P.value 0.00 (figure 4). 
The  mean concentration of high density lipoproteins was significantly decreased in 
psychiatric patient (53.96±17.86) compared to control group (76.88±19.40) with Pvalue 
0.00 (figure5) and Low density lipoproteins mean concentration was significantly 
increased in psychiatric patient (66.42±16.72) compared to control group (34.79±13.09) 
with P.value 0.00 (figure6). 
The correlation analysis showed that LDL was positively correlated with duration of 
using antipsychotic drugs with R-value 0.292, P.value 0.029, (figure7, 8) and there was 
no correlation between duration and age of patients with other parameters. 
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Figure (1): Frequency of males and females in the study group 
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figure(2): Mean concentration of glucose in 
study group
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figure(3): Mean concentration 
ofT.Cholesterol in study group 
 
 
T
r
ig
ly
c
e
r
id
e
  
(m
g
/d
I
)
C a s e C o n tr o l
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
P -v a lu e  0 .0 0 0
 
figure(4): Mean concentration of 
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figure(5): Mean concentration of HDL in 
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triglyceride in study group: 
 
study group :
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figure(6): Mean concentration of LDL in study group  
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 Figure (7): correlation between lipids and 
duration :
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figure(8): correlation between lipids 
and age:
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Tables (1): Difference between male and female: 
Parameters  Male  (Mean±SD) Female 
(Mean±SD) 
P-value 
Glucose (mg/dI) 111.93±24.84 106.25±27.88 0.425 
Total cholesterol  (mg/dI) 171.55±39.37 162.59±44.53 0.430 
Triglyceride  (mg/dI) 166.79±71.50 156.44±43.28 0.512 
HDL  (mg/dI) 58.00±18.15 49.62±16.80 0.079 
LDL  (mg/dI) 68.55±16.19 64.14±17.29 0.330 
Discussion: 
Psychotic patients treated by two types of atypical antipsychotic drugs first one was 
olanzapine as first line and clozapine as second line when patients did not response to first 
line according to psychiatric doctors.Olanzapine and clozapine showed high risk than 
other drugs in weight gain, diabetes mellitus and dyslipidemia. 
(5)
 
In fact these findings in agreement with  study done by Jyoti and et al who reported that, 
one of side effects of antipsychotic drugs was hyperglycemia in fasting blood and 
postprandial blood glucose (due to accumulation of fat in liver and muscle cause insulin 
resistance in tissue). One of the causes is disruption of glucose transport to peripheral 
tissues and due to that it has been suggested the antipsychotic drugs may block glucose 
accumulation directly at the level of the glucose transporter (GLUT) protein in both the 
peripheral and brain tissue, causing hyperglycemia. Another suggested that the cause is 
the blockade of 5HT2A receptor which inhibit the uptake of glucose in skeletal muscle. 
Thirty reasons that is cause derangement of pancreatic function specially beta cells, the 
blockade of muscarinic type 3 (M3) and 5-HT1A receptorsis reasons behind diminished 
of beta cell. Last suggest that is cause insulin resistance. 
(17)
 
These patients are at risk of devolving diabetes mellitus type 2 and diabetic ketoacidosis 
more than other population by causing hyperglycemia and insulin resistance. 
(8, 17)
 
The cases revealed that antipsychotic treated patients slowly had high fasting glucose 
level compared to patients with normal individuals. Total cholesterol had significant 
increase in case group than control group, our study agree with another study, which 
confirmed the elevation of fasting blood glucose level which cause impaired glucose 
tolerance and total cholesterol level in our patients than normal population, that reported 
the hyperglycemia and diabetes mellitus in majority involved who patients used clozapine 
and olanzapine, and showed hypercholesterolemia and hypertriglyceridemia.
(7, 8, 
16)
Similarly triglycerides, HDL and LDL levels had markedly increased in case group 
compared with control group by means and P value, this was agreement with another 
study that found elevation in triglyceride and others. 
(8)
 
All studies proved hyperglycemia and dyslipidemia included that  patients were at high 
risk to develope DM type 2, metabolic syndrome , and hypertension. These side effects 
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put those patients at high risk to develop cardio vascular disorder specially coronary heart 
disease and other cardiac complications. 
(8, 10, 14, 15)
 
This study found positive correlation between duration and LDL which means that when 
patients use antipsychotics drug for long times that will cause more elevation in LDL 
level that will cause severe problems and end with death, but another study did not agree 
with our study results, this  found no correlation between LDL and duration but other 
parameters had positive correlation.
 (17)
 No relation between duration and other 
parameters in interest that means when duration increase have same effect in (glucose, 
total cholesterol, triglyceride, HDL) level.   
There was no correlation between age and lipids change which means that the effect of 
these drugs in lipids in different ages is similar effect. The difference between males and 
females proved that the males had high risk than females, means, stander deviation and p-
value high in males than females. 
 
Conclusion: 
The results of the study concluded that Sudanese psychiatric patients under medications 
had high fasting blood glucose level and lipids profile than normal population. As a 
consequence that might put them at higher risk to develop diabetes mellitus type 2, 
metabolic syndrome, coronary heart disease and other serious disorders if they are left 
without any interventions. 
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